US regulatory status: approved. Molecular target: Fatty-acid amide hydrolase 1.
- Target
- Fatty-acid amide hydrolase 1
- Mechanism
- Cyclooxygenase inhibitor
pharma · Primary Sclerosing Cholangitis (PSC) · No medical condition.
Dr. Falk Pharma
Dr. Falk Pharma GmbH
Dr. Falk Pharma drug portfolio — 15 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Leinenweberstraße 5, Freiburg im Breisgau, Baden-Württemberg 79108, DE HQ
399 Employees
EMA registrant Type
Company details
- Status
- Public
- HQ
- Leinenweberstraße 5, Freiburg im Breisgau, Baden-Württemberg 79108, DE
- Employees
- 399
- Programs
- 11
- Drugs
- 15
- Patents
- 0
Dr. Falk Pharma pipeline
Portfolio lens on 15 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Dr. Falk Pharma drug portfolio — 15 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
Development asset linked to Dr. Falk Pharma in public FDA and regional records.
-
budesonide
Alimentary tract and metabolism (A07)US regulatory status: approved. Molecular target: Glucocorticoid receptor.
- Target
- Glucocorticoid receptor
- Mechanism
- Glucocorticoid receptor agonist
-
Development asset linked to Dr. Falk Pharma in public FDA and regional records.
-
Development asset linked to Dr. Falk Pharma in public FDA and regional records.
-
cholic acid
Alimentary tract and metabolism (A05)US regulatory status: approved. Mechanism: Unknown.
- Mechanism
- Unknown
-
Development asset linked to Dr. Falk Pharma in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Lanosterol 14-alpha demethylase.
- Target
- Lanosterol 14-alpha demethylase
- Mechanism
- Cytochrome P450 51 inhibitor
-
Development asset linked to Dr. Falk Pharma in public FDA and regional records.
-
Development asset linked to Dr. Falk Pharma in public FDA and regional records.
-
Development asset linked to Dr. Falk Pharma in public FDA and regional records.
-
Development asset linked to Dr. Falk Pharma in public FDA and regional records. Molecular target: Bacterial DNA-directed RNA polymerase.
- Target
- Bacterial DNA-directed RNA polymerase
- Mechanism
- Bacterial DNA-directed RNA polymerase inhibitor
-
Development asset linked to Dr. Falk Pharma in public FDA and regional records.
-
Development asset linked to Dr. Falk Pharma in public FDA and regional records.
-
Development asset linked to Dr. Falk Pharma in public FDA and regional records.